Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells

This report addresses whether small molecules can deplete FoxP3-expressing regulatory T (T reg) cells, thereby augmenting antitumor immunity. Imatinib, a tyrosine kinase inhibitor of oncogenic BCR-ABL protein expressed by chronic myelogenous leukemia (CML) cells, possesses off-targets including LCK...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Atsushi, Nishikawa, Hiroyoshi, Noguchi, Shinsuke, Sugiyama, Daisuke, Morikawa, Hiromasa, Takeuchi, Yoshiko, Ha, Danbee, Shigeta, Naoya, Kitawaki, Toshio, Maeda, Yuka, Saito, Takuro, Shinohara, Yoshinori, Kameoka, Yoshihiro, Iwaisako, Keiko, Monma, Fumihiko, Ohishi, Kohshi, Karbach, Julia, Jäger, Elke, Sawada, Kenichi, Katayama, Naoyuki, Takahashi, Naoto, Sakaguchi, Shimon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041710/
https://www.ncbi.nlm.nih.gov/pubmed/31704808
http://dx.doi.org/10.1084/jem.20191009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041710/
https://www.ncbi.nlm.nih.gov/pubmed/31704808
http://dx.doi.org/10.1084/jem.20191009

Ejemplares similares